Mesenchymal Stem Cell and Conventional Immunosuppressant Combination Regimen

This combination therapy represents an immunosuppressive regimen used in solid organ transplantation, particularly for kidney transplants. The regimen combines cellular therapy (mesenchymal stem cells) with multiple conventional immunosuppressive agents to prevent graft rejection. ## Description This is a combination immunosuppressive regimen used in solid organ transplantation, particularly for kidney transplants. The regimen combines: 1. **Mesenchymal stem cells (MSCs)** - Multipotent stromal cells with immunomodulatory properties that can suppress immune responses and promote transplantation tolerance. 2. **Basiliximab** - An anti-CD25 monoclonal antibody that blocks IL-2 receptor activation on T cells. 3. **Methylprednisolone** - A corticosteroid with potent anti-inflammatory and immunosuppressive effects. 4. **Rabbit anti-thymocyte globulin (rATG/Thymoglobulin)** - A polyclonal antibody preparation that depletes T cells and modulates immune responses. 5. **Cyclosporine (CsA)** - A calcineurin inhibitor that prevents T-cell activation. 6. **Mycophenolate mofetil (MMF)** - An inhibitor of purine synthesis that prevents T and B cell proliferation. This multi-modal approach aims to prevent both acute and chronic rejection while potentially allowing for reduced doses of conventional immunosuppressants. Clinical studies have shown that MSCs combined with conventional immunosuppression may increase regulatory T cells, reduce memory T cells, and promote graft tolerance[2][3]. ## Mechanisms of Action The combination works through multiple complementary mechanisms: - **MSCs**: Suppress T-cell responses, induce regulatory T cells, inhibit dendritic cell maturation, and modulate cytokine production[1][3][5] - **Basiliximab**: Blocks IL-2 receptor (CD25) on activated T cells[2] - **Methylprednisolone**: Broad anti-inflammatory effects through inhibition of cytokine production and immune cell function - **Rabbit anti-thymocyte globulin**: Depletes T cells and other immune cells through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity[9] - **Cyclosporine**: Inhibits calcineurin, preventing T-cell activation and IL-2 production[2][5] - **Mycophenolate mofetil**: Inhibits inosine monophosphate dehydrogenase, preventing T and B cell proliferation[2] This combination has been studied in clinical trials for kidney transplantation, with evidence suggesting it may allow for reduced conventional immunosuppression while maintaining effective prevention of graft rejection[2][3][5].

Other names

Combination immunosuppressive regimen for solid organ transplantationMSC-based immunosuppressive regimen